← Leaderboards
Andrei Thomas-Tikhonenko
University Of Pennsylvania
$8,144,872
Attributed
$9,913,601
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,913,601 · 9
By mechanism
R01$4,645,770 · 3
U01$3,537,458 · 1
R21$1,271,626 · 3
R29$280,747 · 1
R03$178,000 · 1
Top collaborators
- Yoseph Barash3 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- M. Celeste Simon$38,172,459
- David C Fajgenbaum$7,024,320
- Yoseph Barash$7,413,836
- Catherine Leona-Grace Wingrove$121,560
- Yan Yuan$11,534,388
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsTumorMutationInhibitor/AntagonistOncogenesIn VivoMicrornasOverexpressionAngiogenesisMalignant NeoplasmsBaseClinical TrialsCell ProliferationRegulationComplexColorectal CancerKras2 GenePharmaceutical PreparationsApoptosisAntineoplastic AgentsMediatingNeovascularizationDown-RegulationAttenuated
Grant awards (27)
Long-read, single-cell RNA sequencing of high-risk neuroblastoma samples$178,000
R03 · FY2025 · CA · contact PI
Cassette exons in neoplastic pro-B-cells: implications for immunotherapy$420,362
U01 · FY2022 · CA · contact PI
Cassette exons in neoplastic pro-B-cells: implications for immunotherapy$185,346
U01 · FY2020 · CA · contact PI
The Myc - miR-17-92 axis in colorectal cancers$372,770
R01 · FY2019 · CA · contact PI
Cassette exons in neoplastic pro-B-cells: implications for immunotherapy$2,931,750
U01 · FY2018 · CA · contact PI
The Myc - miR-17-92 axis in colorectal cancers$384,300
R01 · FY2018 · CA · contact PI
The Myc - miR-17-92 axis in colorectal cancers$384,300
R01 · FY2017 · CA · contact PI
The Myc - miR-17-92 axis in colorectal cancers$384,300
R01 · FY2016 · CA · contact PI
The Myc - miR-17-92 axis in colorectal cancers$384,300
R01 · FY2015 · CA · contact PI
GSK3 inhibition as an adjuvant therapy for Burkitt's lymphoma$255,780
R21 · FY2015 · CA · contact PI
IGF1R gene 3'UTR variants in high-risk pediatric neuroblastoma$212,030
R21 · FY2014 · CA · contact PI
GSK3 inhibition as an adjuvant therapy for Burkitt's lymphoma$146,160
R21 · FY2014 · CA · contact PI
IGF1R gene 3'UTR variants in high-risk pediatric neuroblastoma$182,156
R21 · FY2013 · CA · contact PI
Molecular mechanisms of Myc-induced tumor neovascularization$308,702
R01 · FY2012 · CA · contact PI
Molecular mechanisms of Myc-induced tumor neovascularization$1
R01 · FY2011 · CA · contact PI
Molecular mechanisms of Myc-induced tumor neovascularization$317,062
R01 · FY2010 · CA · contact PI
Molecular mechanisms of Myc-induced tumor neovascularization$299,250
R01 · FY2009 · CA · contact PI
Molecular mechanisms of Myc-induced tumor neovascularization$299,250
R01 · FY2008 · CA · contact PI
Molecular mechanisms of Myc-induced tumor neovascularization$314,012
R01 · FY2007 · CA · contact PI
Interplay between Pax5 and Myc in B-lymphomagenesis$294,073
R01 · FY2006 · CA · contact PI
Interplay between Pax5 and Myc in B-lymphomagenesis$301,150
R01 · FY2005 · CA
Interplay between Pax5 and Myc in B-lymphomagenesis$301,150
R01 · FY2004 · CA
Interplay between Pax5 and Myc in B-lymphomagenesis$301,150
R01 · FY2003 · CA
SUPPRESSION OF B-LYMPHOMAS VIA INDUCTION OF INTERFERONS$237,750
R21 · FY2003 · CA
SUPPRESSION OF B-LYMPHOMAS VIA INDUCTION OF INTERFERONS$237,750
R21 · FY2002 · CA
CONTROL OF THE THROMBOSPONDIN-1 GENE BY MYC ONCOPROTEINS$152,752
R29 · FY2001 · CA
CONTROL OF THE THROMBOSPONDIN-1 GENE BY MYC ONCOPROTEINS$127,995
R29 · FY2000 · CA